Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of MH004 (tofacitinib etocomil) ointment in adolescents and adults with mild to moderate atopic dermatitis
CTR20251236Phase 3Completed
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tofacitinib in atopic dermatitis (AD), sponsored by Minghui Pharmaceutical, Inc.. Started Apr 2025; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20251236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251236.